HH Abakar*, H Guenim, D Labarriere and JP Lagasse

Gastroenterology Department, Orléans University Hospital, Orléans, France

*Corresponding Author: HH Abakar, Gastroenterology Department, Orléans University Hospital, Orléans, France.

Received: November 20, 2025; Published: November 30, 2025

Abstract

Coronavirus disease 2019 (COVID-19) primarily presents with respiratory symptoms. However, it is increasingly recognized as a multisystem condition involving extra-pulmonary complications, including hepatic involvement.

Objective: We report a case of hepatic injury in the form of ischemic sclerosing cholangitis secondary to SARS-CoV-2 infection.

Case Report: A 71-year-old female patient was admitted to the intensive care unit for two months due to COVID-19 viral pneumonia complicated by acute respiratory distress. During the course of her hospitalization, she developed abnormal liver tests suggestive of cholestasis. A diagnosis of post-COVID-19 ischemic cholangitis was established. She was treated with ursodeoxycholic acid combined with bezafibrate. The clinical course was unfavorable, marked by the development of secondary cirrhosis complicated by edema-ascites decompensation. Given her age, liver transplantation was not considered.

Conclusion: Post-COVID-19 ischemic cholangitis is a rare but serious complication. It should be considered in the presence of persistent cholestasis following severe COVID-19 pneumonia.

Keywords: COVID-19 Pneumonia; Cholestasis; Ischemic Cholangitis

References

1. Edwards K., et al. “Secondary sclerosing cholangitis in critically ill patients: A rare disease precipitated by severe SARS-CoV-2 infection”. BMJ Case Report 13 (2020): e237984.
2. Roth NC., et al. “Post-COVID-19 Cholangiopathy: A Novel Entity”. The American Journal of Gastroenterology 116 (2021): 1077-1082.
3. Faruqui S., et al. “Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications”. The American Journal of Gastroenterology 116 (2021): 1414-1425.
4. Arnstadt B., et al. “Corona again? SSC after a severe COVID- disease”. Gastroenterology 59 (2021): 1304-1308.
5. Leonhardt S., et al. “Hepatobiliary long-term consequences of COVID-19: Dramatically increased rate of secondary sclerosing cholangitis in critically ill COVID-19 patients”. Hepatology International 17 (2023): 1610-1625.
6. Hartl L., et al. “Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease”. Hepatology 76 (2022): 1563-1575.
7. Butikofer S., et al. “Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19”. Liver International 41 (2021): 2404-2417.
8. Hunyady P., et al. “Secondary sclerosing cholangitis following coronavirus disease 2019 (COVID-19): a multicenter retrospective study”. Clinical Infectious Disease 76 (2023): e179-e187.
9. Christoph R Werner., et al. “Incidence of Secondary Sclerosing Cholangitis in Hospitalized Long COVID-19 Patients: A Retrospective Single Center Study” (2024).
10. Faruqui S., et al. “Bile duct injury and severe cholestasis in patients recovering from severe COVID-19: A novel entity of COVID-associated cholangiopathy”. AASLD Digital Express 42 (2020).
11. Henrie J., et al. “Profile of liver cholestatic biomarkers following prolonged ketamine administration in patients with COVID-19”. BMC Anesthesiology 23 (2023): 44.
12. Leonhardt S., et al. “Secondary Sclerosing Cholangitis in Critically Ill Patients: Clinical Presentation, Cholangiographic Features, Natural History, and Outcome: A Series of 16 Cases”. Medicine (Baltimore) 94 (2015): e2188.
13. Sharma A., et al. “Liver disease and outcomes among COVID-19 hospitalized patients - A systematic review and meta-analysis”. Annals of Hepatology 21 (2021): 100273.
14. Chan HL., et al. “Clinical significance of hepatic derangement in severe acute respiratory syndrome”. World Journal of Gastroenterology (2005).
15. Zhao B., et al. “Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids”. Protein Cell (2021).
16. Kaltschmidt B., et al. “Hepatic Vasculopathy and Regenerative Responses of the Liver in Fatal Cases of COVID-19”. Clinical Gastroenterology and Hepatology (2021).
17. Faruqui S., et al. “Biliary tract injury in patients with COVID-19: a review of the current literature”. Gastroenterology and Hepatology (2022).
18. Ghafoor S., et al. “Imaging features of COVID-19-associated secondary sclerosing cholangitis on magnetic resonance cholangiopancreatography: a retrospective analysis”. Insights Imaging 13 (2022): 128.
19. Yanny B., et al. “Post-COVID-19 cholangiopathy: a systematic review”. Journal of Clinical and Experimental Hepatology 13 (2023): 489-499.
20. Heucke N and Keitel V. “COVID-19-associated cholangiopathy: what is left after the virus has gone?” Hepatology 76 (2022): 1560-1562.
21. Veerankutty FH., et al. “Post-COVID-19 cholangiopathy: current understanding and management options”. World Journal of Gastrointestinal Surgery 15 (2023): 788-798.
22. Seo N., et al. “Sclerosing cholangitis: clinicopathologic features, imaging spectrum, and systemic approach to differential diagnosis”. Korean Journal of Radiology 17 (2016): 25-38.
23. Kulkarni AV., et al. “Post-COVID-19 cholestasis: a case series and review of literature”. Journal of Clinical and Experimental Hepatology 12 (2022): 1580-1590.
24. Durazo FA., et al. “Post-COVID-19 Cholangiopathy—A New Indication for Liver Transplantation: A Case Report”. Transplantation Proceedings 53 (2021): 1132-1137.
25. Ferreira FB., et al. “COVID-19-associated secondary sclerosing cholangitis—A case series of 4 patients”. Clinics and Research in Hepatology and Gastroenterology 46 (2022): 102048.
26. Tsutsumi T., et al. “Association of coagulopathy with liver dysfunction in patients with COVID-19”. Hepatology Research2 (2021): 227-232.
27. Shih AR., et al. “Persistent Cholestatic Injury and Secondary Sclerosing Cholangitis in COVID-19 Patients”. Archives of Pathology and Laboratory Medicine 146 (2022): 1184-1193.
28. Esposito I., et al. “Secondary sclerosing cholangitis after intensive care unit treatment: Clues to the histopathological differential diagnosis”. Virchows Archiv 453 (2008): 339-345.
29. Aguilar MT and Chascsa DM. “Update on emerging treatment options for primary biliary cholangitis”. Hepatology Medicine 12 (2020): 69-77.
30. Engler S., et al. “Progressive sclerosing cholangitis after septic shock: a new variant of vanishing bile duct disorders”. Gut 52 (2003): 688-693.
31. Voigtlander T., et al. “Secondary sclerosing cholangitis in critically ill patients: model of end-stage liver disease score and renal function predict outcome”. Endoscopy (2012).
32. Keta-Cov research group. Electronic address vmaf, Keta-Cov research g. “Intravenous ketamine and progressive cholangiopathy in COVID-19 patients”. Journal of Hepatology5 (2021): 1243-1244
33. Voigtlander T., et al. “Liver transplantation for critically Ill patients with secondary sclerosing cholangitis: outcome and complications”. Liver Transplantation10 (2015): 1295-1299.

Citation

Citation: HH Abakar., et al. “Ischaemic Sclerosing Cholangitis Post COVID-19: A Case Report".Acta Scientific Gastrointestinal Disorders 8.12 (2025): 22-28.

Copyright

Copyright: © 2025 HH Abakar., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.